-
Utility of ctDNA to support patient selection for early phase clinical trials: The TARGET Study
Study
EGAS00001003407
-
DNA Methylation loss coupled with mitotic cell division promotes immune evasion of tumours with high mutation load
Study
EGAS00001003731
-
Whole-exome sequencing and microRNA profiling predicted relapse risk of stage I lung adenocarcinomas
Study
EGAS00001004461
-
Mutations in the RAS/MAPK pathway drive replication repair deficient hypermutated tumors and confer sensitivity to MEK inhibition
Study
EGAS00001005008
-
A Proteogenomic Analysis of Clear Cell Renal Cell Carcinoma in a Chinese Population
Study
EGAS00001006005
-
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab
Study
EGAS00001006004
-
Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis
Study
EGAS00001005982
-
WGS of MAPKi acquired resistant samples from patients and PDX models
Study
EGAS00001006874
-
Metastatic Colorectal Adenocarcinoma Tumor Purity Assessment from Whole Exome Sequencing Data
Study
phs003059
-
GeneScreen, a Population Based, Targeted Genomic Screening Study
Study
phs001817